Cavendish backs Optima Health after interim update shows 60% revenue growth and lower debt

Cavendish rated Optima Health PLC a 'buy' with a 302p target price after a trading update indicated the company remains on track to meet full-year forecasts. First-half revenue was about £96 million, up 60% year on year for the six months to the end of September 2026, supported by the PAM acquisition and continued organic growth.

Analysis

The key underwriting question is whether PAM adds durable earnings or mainly enlarges the revenue base: acquisition-led growth can conceal slowing like-for-like demand, while integration, client retention and cross-selling determine whether the deal compounds value. If employers continue outsourcing occupational health, scaled providers may gain procurement advantage; smaller and private competitors could face pressure to match breadth and contract capacity. That benefit is conditional, not established by revenue growth alone.

Near term, the broker reiteration may support sentiment, but a single broker target is not independent confirmation of forecast delivery. Over the next 1–3 months, the useful catalysts are full-year results and disclosure on organic growth, margins, cash conversion and PAM integration. Over 6–18 months, successful cross-selling and retention would support a stronger growth profile; weak conversion of acquired revenue into cash or renewed acquisition-led expansion could instead expose execution and balance-sheet risk. The bullish case is falsified by a forecast downgrade, deterioration in organic growth, evidence of client losses, or weaker cash conversion. Valuation and liquidity data are absent, so the target price alone does not establish upside or risk/reward.

Key Decisions for Investors

• Treat OPT as a watchlist/conditional long, not a momentum buy based solely on the broker rating. Consider entry only after checking valuation, share liquidity and whether guidance is supported by operating metrics.
• At the next results, separate organic from acquired growth and monitor PAM client retention, cross-selling, operating margins and cash conversion. If revenue growth remains acquisition-heavy without improving cash generation, avoid adding or reassess the thesis.
• Do not infer a trade in Cavendish (CAV) from its research call; the article provides no evidence of a material earnings link between the broker and OPT.
• Falsification trigger: a full-year forecast reduction, weaker-than-expected organic growth, or signs that integration is impairing retention or cash conversion. No options or pair trade is warranted without valuation, liquidity and peer-comparability data.